HBCP(HBCP)
HBCP
Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.
Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.
| Metric | FY2026E | FY2027E |
|---|---|---|
| Revenue Avg | $156M | $163M |
| Low | $155M | $159M |
| High | $157M | $165M |
| EBITDA Avg | $53M | $55M |
| Low | $52M | $54M |
| High | $53M | $56M |
| EBIT Avg | $49M | $52M |
| Low | $49M | $50M |
| High | $50M | $52M |
| Net Income Avg | $47M | $49M |
| Low | $46M | $49M |
| High | $47M | $50M |
| EPS Avg | $5.95 | $6.26 |
| Low | $5.92 | $6.19 |
| High | $6.02 | $6.40 |
| Analysts (Rev / EPS) | 3 / 3 | 3 / 3 |
| Metric | Q3 2026 | Q4 2026 | Q1 2027 | Q2 2027 | Q3 2027 | Q4 2027 |
|---|---|---|---|---|---|---|
| Revenue Avg | $39M | $40M | $40M | $40M | $41M | $42M |
| Low | $39M | $40M | $39M | $40M | $41M | $42M |
| High | $40M | $40M | $40M | $41M | $41M | $42M |
| EBITDA Avg | $13M | $13M | $13M | $14M | $14M | $14M |
| Low | $13M | $13M | $13M | $14M | $14M | $14M |
| High | $13M | $14M | $13M | $14M | $14M | $14M |
| EBIT Avg | $12M | $13M | $13M | $13M | $13M | $13M |
| Low | $12M | $13M | $12M | $13M | $13M | $13M |
| High | $13M | $13M | $13M | $13M | $13M | $13M |
| Net Income Avg | $12M | $12M | $12M | $12M | $13M | $13M |
| Low | $12M | $12M | $12M | $12M | $12M | $13M |
| High | $12M | $12M | $12M | $12M | $13M | $13M |
| EPS Avg | $1.51 | $1.53 | $1.49 | $1.54 | $1.60 | $1.63 |
| Low | $1.49 | $1.52 | $1.48 | $1.53 | $1.59 | $1.62 |
| High | $1.53 | $1.54 | $1.51 | $1.56 | $1.61 | $1.64 |
| Analysts (Rev / EPS) | 3 / 3 | 2 / 1 | 1 / 1 | 2 / 1 | 2 / 1 | 1 / 1 |